Skip to main content
. 2019 Apr 5;234(10):18731–18747. doi: 10.1002/jcp.28513

Figure 1.

Figure 1

Adenoviral CTRP9 delivery ameliorates cardiac function on Day 7 post MI. Ad‐CTRP9 or Ad‐GFP was injected into the jugular vein of rats 5 days before MI. (a–c) Effects of adenoviral CTRP9 supplementation on plasma and tissue CTRP9 protein levels by ELISA and western blot analysis. (d) Survival rate according to survival curve analysis (MI, n = 21, Ad‐GFP, n = 18; Ad‐CTRP9, n = 17). (e,f) Cardiac Masson trichrome staining and infarct area (per group, n = 5). (g–i) Quantitative analysis of the LVEDD, EF, and FS of rat hearts pretreated with Ad‐CTRP9 or Ad‐GFP (per group, successively, n = 7, 6, 6, and 7). *p < 0.05 and **p < 0.01, the connection represents a comparison between two groups. CTRP9: C1q/TNF‐related protein‐9; EF: ejection fraction; ELISA: enzyme‐linked immunosorbent assay; FS, fractional shortening; GAPDH: glyceraldehyde 3‐phosphate dehydrogenase; GFP: green fluorescent protein; LVEDD: left ventricular end‐diastolic dimension; MI: myocardial infarction [Color figure can be viewed at wileyonlinelibrary.com]